Study could pave way for new antiviral, as China grapples with Covid wave

A trial of a Chinese-developed derivative of remdesevir showed comparable efficacy to Paxlovid in a study published in NEJM.

When Eric Xu fell sick and tested positive with Covid this month, he took pills of his own invention. 

Paxlovid, the primary oral antiviral available in the U.S., is in short supply in China. But Xu, a prominent biochemist at the Chinese Academy of Sciences, had helped devise his own in 2021 and, as the drug’s inventor, could legally take it even as it went through clinical trials. 

Read the rest…